To reduce the risk of serious infection, patients who receive systemic chemotherapy are often
empirically treated with prophylactic antibiotics (eg, ciprofloxacin) to prevent commensal
organisms from invading and with granulocyte-stimulating agents (eg, filgrastim) to increase
neutrophil count.
